Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001880623 | SCV002120445 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2022-08-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002482482 | SCV002790903 | uncertain significance | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2022-01-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003247059 | SCV003941023 | uncertain significance | Inborn genetic diseases | 2023-06-01 | criteria provided, single submitter | clinical testing | The c.3338C>T (p.P1113L) alteration is located in exon 16 (coding exon 15) of the CACNA1H gene. This alteration results from a C to T substitution at nucleotide position 3338, causing the proline (P) at amino acid position 1113 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV004693805 | SCV005194078 | uncertain significance | not provided | criteria provided, single submitter | not provided |